RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:1467

Cogan syndrome

medium confidenceDisorder

Publications

729

81.1th percentile

Trials

1

Interventional, condition-specific

Researchers

1,033

Distinct authors in sample

Gene link

—

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare inflammatory/autoimmune disorder of unknown origin characterized by interstitial keratitis (IK) and audiovestibular dysfunctions.

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    729 matched papers (410 in last 10 years) Source

  3. Phenotype characterisedPresent

    20 HPO annotations (e.g. Vertigo; Conjunctivitis; Scleritis) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    1 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

20

Associated phenotypes · MONDO:0015453

  • Vertigo
  • Conjunctivitis
  • Scleritis
  • Keratitis
  • Sensorineural hearing impairment

Showing 5 of 20 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

729

729 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

729 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

410 in the last 10 years · medium confidence · 81.1th percentile (publications denominator)

Phrase hits: 729 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,033

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Mekinian A4 papers · 2025

    AP-HP, Hôpital Saint-Antoine, service de médecine interne and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Sorbonne Universités, UPMC University, Paris 06, F-75012, Paris, France. Electronic address: arsene.mekinian@aphp.fr.

    Papers in Europe PMC
  2. 02
    Bogdanos DP3 papers · 2026

    Unit of Immunonutrition and Clinical Nutrition, Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis campus, Biopolis, Larissa, Greece.

    Papers in Europe PMC
  3. 03
    Choi JY3 papers · 2025

    From the Department of Neurology (S.-U.L.), Korea University Anam Hospital; Department of Neurology (S.-U.L., J.-S.K., J.-Y.C.), Dizziness Center, Clinical Neuroscience Center, and Department of Neurology (J.-S.K., J.-Y.C.), Department of Ophthalmology (J.Y.H.), and Department of Otolaryngology-Head and Neck Surgery (J.-J.S.), Seoul National University College of Medicine, Division of Rheumatology, Department of Internal Medicine (Y.-J.H.), and Research Administration Team (H.-J.K.), Seoul National University Bundang Hospital, Seongnam, South Korea; and Department of Neurology (X.Y.), Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Peking, China.

    Papers in Europe PMC
  4. 04
    Goulis DG3 papers · 2026

    Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.

    Papers in Europe PMC
  5. 05
    Grammatikopoulou MG3 papers · 2026

    Unit of Immunonutrition and Clinical Nutrition, Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis campus, Biopolis, Larissa, Greece. mgrammat@uth.gr.

    Papers in Europe PMC
  6. 06
    Katsiari CG3 papers · 2026

    Unit of Immunonutrition and Clinical Nutrition, Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis campus, Biopolis, Larissa, Greece.

    Papers in Europe PMC
  7. 07
    Kim JS3 papers · 2025

    From the Department of Neurology (S.-U.L.), Korea University Anam Hospital; Department of Neurology (S.-U.L., J.-S.K., J.-Y.C.), Dizziness Center, Clinical Neuroscience Center, and Department of Neurology (J.-S.K., J.-Y.C.), Department of Ophthalmology (J.Y.H.), and Department of Otolaryngology-Head and Neck Surgery (J.-J.S.), Seoul National University College of Medicine, Division of Rheumatology, Department of Internal Medicine (Y.-J.H.), and Research Administration Team (H.-J.K.), Seoul National University Bundang Hospital, Seongnam, South Korea; and Department of Neurology (X.Y.), Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Peking, China. jisookim@snu.ac.kr.

    Papers in Europe PMC
  8. 08
    Kontouli KM3 papers · 2026

    Department of Primary Education, School of Education, University of Ioannina, Ioannina, Greece.

    Papers in Europe PMC
  9. 09
    Lee SU3 papers · 2025

    From the Department of Neurology (S.-U.L.), Korea University Anam Hospital; Department of Neurology (S.-U.L., J.-S.K., J.-Y.C.), Dizziness Center, Clinical Neuroscience Center, and Department of Neurology (J.-S.K., J.-Y.C.), Department of Ophthalmology (J.Y.H.), and Department of Otolaryngology-Head and Neck Surgery (J.-J.S.), Seoul National University College of Medicine, Division of Rheumatology, Department of Internal Medicine (Y.-J.H.), and Research Administration Team (H.-J.K.), Seoul National University Bundang Hospital, Seongnam, South Korea; and Department of Neurology (X.Y.), Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Peking, China.

    Papers in Europe PMC
  10. 10
    Pardali EC3 papers · 2026

    Unit of Immunonutrition and Clinical Nutrition, Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis campus, Biopolis, Larissa, Greece.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

1

interventional trials for this specific condition

1 interventional trial matched this specific condition name; none in our sample are currently recruiting.

Data as of 11 September 2026

1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).

medium confidence · 80.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

1 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (1)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Cogan syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Cogan syndrome"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Cogan syndrome"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T17:29:05.468Z